DiPiro J T, Hamilton R G, Howdieshell T R, Adkinson N F, Mansberger A R
University of Georgia College of Pharmacy, Athens, USA.
Clin Diagn Lab Immunol. 1994 May;1(3):295-8. doi: 10.1128/cdli.1.3.295-298.1994.
Antilipopolysaccharide (anti-LPS) immunoglobulin G (IgG) and IgM have been associated with protection from LPS effects in vivo. We investigated the presence of IgE and anti-LPS in 32 patients that had experienced severe traumatic injury and in 35 healthy volunteers; we also investigated whether IgE anti-LPS was associated with important clinical events. Plasma samples were collected daily from patients in the intensive care unit and on one occasion from volunteers; the samples were assayed for IgE anti-LPS. IgE anti-LPS was assayed by enzyme-linked immunosorbent assay with monoclonal anti-human IgE as the capture antibody. Detection was accomplished with biotin-labeled LPS (Escherichia coli J5 mutant) followed by streptavidin-peroxidase with 2,2'-azino(3-ethylbenzthiazoline)sulfonic acid as the substrate. The assay was demonstrated to be specific for IgE and LPS-biotin by nonreactivity of control sera with high-titer anti-LPS IgG and IgM and by inhibition with unlabeled LPS. IgE anti-LPS was detected in 1 of 35 healthy controls (2.9%) and 25 of 32 traumatically injured patients (78%) (P < 0.001). The presence of IgE anti-LPS was associated with a lower incidence of death (P = 0.026) and of renal failure (P = 0.0012). There was no apparent temporal relationship between detection of IgE anti-LPS and clinical events. IgG anti-LPS was detected more frequently in patients that were positive for IgE anti-LPS (P = 0.06) but was not associated with clinical events. The inability to detect IgE anti-LPS may be related to adverse clinical events through depletion of specific IgE due to LPS exposure after trauma or through saturation of the assay by IgE with other specificities. We have reported increased total IgE concentrations in these patients. (J.T. DiPiro, R.G. Hamilton, T. R. Howdieshell, N. F. Adkinson, and A. R. Mansberger, Ann. Surg. 215:460-466, 1992).
抗脂多糖(抗LPS)免疫球蛋白G(IgG)和IgM与体内免受LPS影响有关。我们调查了32例严重创伤患者和35名健康志愿者体内IgE和抗LPS的存在情况;我们还研究了IgE抗LPS是否与重要临床事件相关。每天从重症监护病房的患者中采集血浆样本,志愿者仅采集一次;对样本进行IgE抗LPS检测。采用以单克隆抗人IgE作为捕获抗体的酶联免疫吸附测定法检测IgE抗LPS。用生物素标记的LPS(大肠杆菌J5突变体)进行检测,随后以链霉亲和素 - 过氧化物酶,以2,2'-联氮基-双-(3-乙基苯并噻唑啉-6-磺酸)为底物。通过对照血清与高滴度抗LPS IgG和IgM无反应以及未标记LPS的抑制作用,证明该测定法对IgE和LPS-生物素具有特异性。在35名健康对照者中有1名(2.9%)检测到IgE抗LPS,在32例创伤患者中有25名(78%)检测到(P<0.001)。IgE抗LPS的存在与较低的死亡率(P = 0.026)和肾衰竭发生率(P = 0.0012)相关。IgE抗LPS的检测与临床事件之间没有明显的时间关系。在IgE抗LPS呈阳性的患者中更频繁地检测到IgG抗LPS(P = 0.06),但与临床事件无关。无法检测到IgE抗LPS可能通过创伤后LPS暴露导致特异性IgE耗竭或通过具有其他特异性的IgE使测定法饱和而与不良临床事件相关。我们已报道这些患者的总IgE浓度升高。(J.T.迪皮罗、R.G.汉密尔顿、T.R.豪迪谢尔、N.F.阿德金森和A.R.曼斯伯格,《外科学年鉴》215:460 - 466,1992)